Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -39.96% is 71% above its 5-year average of -135.53%, near the high end of its 5-year range (-331.82%–-32.37%).
4.46% above its 12-month average of -41.83%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -32.37%.
NET PROFIT MARGIN
-39.96%
NET PROFIT MARGIN AVG TTM
-41.83%
NET PROFIT MARGIN AVG 3Y
-52.10%
NET PROFIT MARGIN AVG 5Y
-135.53%
NET PROFIT MARGIN AVG 10Y
-761.75%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.46%
CURRENT VS 3Y AVG
+23.30%
CURRENT VS 5Y AVG
+70.52%
CURRENT VS 10Y AVG
+94.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-11317.14%
vs the sector median at left
electroCore, Inc.
Market Cap
$89.44M
Net Profit Margin
-39.96%
TTM Avg
-41.83%
3Y Avg
-52.10%
5Y Avg
-135.53%
Market Cap
$89.78M
Net Profit Margin
0.00%
TTM Avg
-9.81%
3Y Avg
-113.18%
5Y Avg
-75.45%
Market Cap
$90.20M
Net Profit Margin
2.57%
TTM Avg
-5.95%
3Y Avg
-14.59%
5Y Avg
-10.91%
Market Cap
$90.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$90.64M
Net Profit Margin
7051.24%
TTM Avg
-5065.26%
3Y Avg
-2532.63%
5Y Avg
-1688.42%
Market Cap
$87.96M
Net Profit Margin
6.21%
TTM Avg
8.02%
3Y Avg
-5.41%
5Y Avg
-4.66%
Market Cap
$87.85M
Net Profit Margin
-269.42%
TTM Avg
-19.58%
3Y Avg
-904.79%
5Y Avg
-881.91%
Market Cap
$87.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$85.86M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $89.44M | -39.96% | -41.83% | -52.10% | -135.53% |
| Equillium, Inc. (EQ)vs › | $89.78M | 0.00% | -9.81% | -113.18% | -75.45% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 2.57% | -5.95% | -14.59% | -10.91% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 7051.24% | -5065.26% | -2532.63% | -1688.42% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 6.21% | 8.02% | -5.41% | -4.66% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | -269.42% | -19.58% | -904.79% | -881.91% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | -1.41% | 0.88% | 1.31% | 1.31% |
Operating Margin
-37.6%
Net Profit Margin
-40.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -32.37% |
| 2026-03-31 | -55.00% |
| 2025-12-31 | -32.84% |
| 2025-09-30 | -39.19% |
| 2025-06-30 | -49.74% |
| 2025-03-31 | -57.37% |
| 2024-12-31 | -45.81% |
| 2024-09-30 | -38.10% |
| 2024-06-30 | -43.25% |
| 2024-03-31 | -64.41% |
| 2023-12-31 | -77.67% |
| 2023-09-30 | -89.44% |
| 2023-06-30 | -138.07% |
| 2023-03-31 | -211.04% |
| 2022-12-31 | -226.17% |
| 2022-09-30 | -275.96% |
| 2022-06-30 | -247.43% |
| 2022-03-31 | -293.94% |
| 2021-12-31 | -331.82% |
| 2021-09-30 | -268.53% |
| 2021-06-30 | -228.05% |
| 2021-03-31 | -447.18% |
| 2020-12-31 | -681.25% |
| 2020-09-30 | -415.08% |
| 2020-06-30 | -629.72% |
| 2020-03-31 | -1084.72% |
| 2019-12-31 | -1259.08% |
| 2019-09-30 | -1564.84% |
| 2019-06-30 | -1943.23% |
| 2019-03-31 | -3384.15% |
| 2018-12-31 | -4172.26% |
| 2018-09-30 | -8745.95% |
| 2018-06-30 | -4524.68% |
| 2018-03-31 | -11699.58% |
| 2017-12-31 | -2345.45% |
| 2017-09-30 | -4364.53% |
| 2017-06-30 | -6552.05% |
| 2017-03-31 | -5436.38% |
